Research progress of ubiquitin-proteasome system in hepatic ischemia-reperfusion injury

doi:10.3877/cma.j.issn.1674-3903.2022.01.009

Abstract

Abstract:

Ubiquitin-proteasome system (UPS) is an adenosine triphosphate-dependent non-lysosomal protein degradation system in cells. It plays a role in many signal transduction pathways and can regulate a variety of cell biological processes, such as cell cycle regulation, signal transduction, apoptosis, DNA repair and gene expression and so on. Hepatic ischemia-reperfusion injury (HIRI) is a common pathophysiological phenomenon of liver transplantation and hepatectomy, which is one of the most important factors affecting the prognosis of patients. Recently, more and more studies have begun to focus on the role of UPS in the occurrence and development of HIRI, which provides new ideas and potential therapeutic targets for the clinical treatment and prevention of HIRI. This paper will review the research progress of UPS in HIRI.

Key words: Ubiquitin-proteasome system, Ischemia-reperfusion injury, Signal transduction, Liver transplantation

Jiayu Guo, Tao Qiu, Bo Yu. Research progress of ubiquitin-proteasome system in hepatic ischemia-reperfusion injury[J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(01): 49-54.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2022.01.009

https://zhyzzz.cma-cmc.com.cn/EN/Y2022/V16/I01/49

References 58

1	Dar WA, Sullivan E, Bynon JS, et al. Ischaemia reperfusion injury in liver transplantation: cellular and molecular mechanisms[J]. Liver Int, 2019, 39(5): 788-801.
2	Konishi T, Lentsch AB. Hepatic ischemia/reperfusion: mechanisms of tissue injury, repair, and regeneration[J]. Gene Expr, 2017, 17(4): 277-287.
3	Zhou J, Chen J, Wei Q, et al. The role of ischemia/reperfusion injury in early hepatic allograft dysfunction[J]. Liver Transpl, 2020, 26(8): 1034-1048.
4	Padrissa-Altes S, Zaouali MA, Bartrons R, et al. Ubiquitin-proteasome system inhibitors and AMPK regulation in hepatic cold ischaemia and reperfusion injury: possible mechanisms[J]. Clin Sci (Lond), 2012, 123(2): 93-98.
5	Kwon YT, Ciechanover A. The ubiquitin code in the ubiquitin-proteasome system and autophagy[J]. Trends Biochem Sci, 2017, 42(11): 873-886.
6	Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment[J]. Arch Pharm Res, 2020, 43(11): 1144-1161.
7	Spanig S, Kellermann K, Dieterlen MT, et al. The ubiquitin proteasome system in ischemic and dilated cardiomyopathy[J]. Int J Mol Sci, 2019, 20(24): 6354.
8	Cao J, Zhong MB, Toro CA, et al. Endo-lysosomal pathway and ubiquitin-proteasome system dysfunction in Alzheimer′s disease pathogenesis[J]. Neurosci Lett, 2019, 703: 68-78.
9	Luza S, Opazo CM, Bousman CA, et al. The ubiquitin proteasome system and schizophrenia[J]. Lancet Psychiatry, 2020, 7(6): 528-537.
10	Nam T, Han JH, Devkota S, et al. Emerging paradigm of crosstalk between autophagy and the ubiquitin-proteasome system[J]. Mol Cells, 2017, 40(12): 897-905.
11	Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy[J]. Science, 2019, 366(6467): 818-822.
12	Varshavsky A. The ubiquitin system, autophagy, and regulated protein degradation[J]. Annu Rev Biochem, 2017, 86: 123-128.
13	Zheng N, Shabek N. Ubiquitin ligases: structure, function, and regulation[J]. Annu Rev Biochem, 2017, 86: 129-157.
14	Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases[J]. Nat Rev Mol Cell Biol, 2009, 10(6): 398-409.
15	Xu L, Fan J, Wang Y, et al. An activity-based probe developed by a sequential dehydroalanine formation strategy targets HECT E3 ubiquitin ligases[J]. Chem Commun (Camb), 2019, 55(49): 7109-7112.
16	Zhou W, Zhong ZB, Lin DN, et al. Hypothermic oxygenated perfusion inhibits HECTD3-mediated TRAF3 polyubiquitination to alleviate DCD liver ischemia-reperfusion injury[J]. Cell Death Dis, 2021, 12(2): 211.
17	Hu JF, Zhu XH, Zhang XJ, et al. Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury[J]. J Hepatol, 2016, 64(1): 146-159.
18	Jiang QY, Li FB, Cheng Z, et al. The role of E3 ubiquitin ligase HECTD3 in cancer and beyond[J]. Cell Mol Life Sci, 2020, 77(8): 1483-1495.
19	Jiang WW, Kong LL, Ni QF, et al. miR-146a ameliorates liver ischemia/reperfusion injury by suppressing IRAK1 and TRAF6[J]. PLoS One, 2014, 9(7): e101530.
20	Huang ZT, Zheng DF, Pu JL, et al. MicroRNA-125b protects liver from ischemia/reperfusion injury via inhibiting TRAF6 and NF-kappaB pathway[J]. Biosci Biotechnol Biochem, 2019, 83(5): 829-835.
21	Xu XL, Zhang ZC, Lu YJ, et al. ARRB1 ameliorates liver ischaemia/reperfusion injury via antagonizing TRAF6-mediated Lysine 6-linked polyubiquitination of ASK1 in hepatocytes[J]. J Cell Mol Med, 2020, 24(14): 7814-7828.
22	Luo YH, Huang ZT, Zong KZ, et al. miR-194 ameliorates hepatic ischemia/reperfusion injury via targeting PHLDA1 in a TRAF6-dependent manner[J]. Int Immunopharmacol, 2021, 96: 107604.
23	Detry O, Deroover A, Meurisse N, et al. Donor age as a risk factor in donation after circulatory death liver transplantation in a controlled withdrawal protocol programme[J]. Br J Surg, 2014, 101(7): 784-792.
24	Li Y, Ruan DY, Jia CC, et al. Aging aggravates hepatic ischemia-reperfusion injury in mice by impairing mitophagy with the involvement of the EIF2alpha-parkin pathway[J]. Aging (Albany NY), 2018, 10(8): 1902-1920.
25	Ning XJ, Yan X, Wang YF, et al. Parkin deficiency elevates hepatic ischemia/reperfusion injury accompanying decreased mitochondrial autophagy, increased apoptosis, impaired DNA damage repair and altered cell cycle distribution[J]. Mol Med Rep, 2018, 18(6): 5663-5668.
26	Gladkova C, Maslen SL, Skehel JM, et al. Mechanism of parkin activation by PINK1[J]. Nature, 2018, 559(7714): 410-414.
27	Gu J, Zhang T, Guo JR, et al. PINK1 activation and translocation to mitochondria-associated membranes mediates mitophagy and protects against hepatic ischemia/reperfusion injury[J]. Shock, 2020, 54(6): 783-793.
28	Saidi RF, Rajeshkumar B, Shariftabrizi A, et al. Human adipose-derived mesenchymal stem cells attenuate liver ischemia-reperfusion injury and promote liver regeneration[J]. Surgery, 2014, 156(5): 1225-1231.
29	Pan GZ, Yang Y, Zhang J, et al. Bone marrow mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injuries via inactivation of the MEK/ERK signaling pathway in rats[J]. J Surg Res, 2012, 178(2): 935-948.
30	Sun CK, Chang CL, Lin YC, et al. Systemic administration of autologous adipose-derived mesenchymal stem cells alleviates hepatic ischemia-reperfusion injury in rats[J]. Crit Care Med, 2012, 40(4): 1279-1290.
31	Zheng J, Chen L, Lu TY, et al. MSCs ameliorate hepatocellular apoptosis mediated by PINK1-dependent mitophagy in liver ischemia/reperfusion injury through AMPKα activation[J]. Cell Death Dis, 2020, 11(4): 256.
32	Bai X, Zhang YL, Liu LN. Inhibition of TRIM8 restrains ischaemia-reperfusion-mediated cerebral injury by regulation of NF-kappaB activation associated inflammation and apoptosis[J]. Exp Cell Res, 2020, 388(2): 111818.
33	Yan FJ, Zhang XJ, Wang WX, et al. The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis[J]. Hepatology, 2017, 65(5): 1492-1511.
34	Qiu T, Wang TY, Zhou JQ, et al. Tripartite motif 8 deficiency relieves hepatic ischaemia/reperfusion injury via TAK1-dependent signalling pathways[J]. Int J Biol Sci, 2019, 15(8): 1618-1629.
35	Chen SY, Zhang HP, Li J, et al. Tripartite motif-containing 27 attenuates liver ischemia/reperfusion injury by suppressing transforming growth factor beta-activated kinase 1 (TAK1) by TAK1 binding protein 2/3 degradation[J]. Hepatology, 2021, 73(2): 738-758.
36	Athanasopoulos V, Ramiscal RR, Vinuesa CG. ROQUIN signalling pathways in innate and adaptive immunity[J]. Eur J Immunol, 2016, 46(5): 1082-1090.
37	Zheng L, Ling W, Zhu DM, et al. Roquin-1 regulates macrophage immune response and participates in hepatic ischemia-reperfusion injury[J]. J Immunol, 2020, 204(5): 1322-1333.
38	Li TT, Luo YH, Yang H, et al. FBXW5 aggravates hepatic ischemia/reperfusion injury via promoting phosphorylation of ASK1 in a TRAF6-dependent manner[J]. Int Immunopharmacol, 2021, 99: 107928.
39	Bard JAM, Goodall EA, Greene ER, et al. Structure and function of the 26S proteasome[J]. Annu Rev Biochem, 2018, 87: 697-724.
40	Collins GA, Goldberg AL. The logic of the 26S proteasome[J]. Cell, 2017, 169(5): 792-806.
41	Alva N, Panisello-Roselló A, Flores M, et al. Ubiquitin-proteasome system and oxidative stress in liver transplantation[J]. World J Gastroenterol, 2018, 24(31): 3521-3530.
42	Tan CRC, Abdul-Majeed S, Cael B, et al. Clinical pharmacokinetics and pharmacodynamics of bortezomib[J]. Clin Pharmacokinet, 2019, 58(2): 157-168.
43	Zaouali MA, Bardag-Gorce F, Carbonell T, et al. Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury[J]. Exp Mol Pathol, 2013, 94(2): 352-359.
44	Bejaoui M, Zaouali MA, Folch-Puy E, et al. Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways[J]. J Pharm Pharmacol, 2014, 66(1): 62-72.
45	Panisello-Rosello A, Verde E, Zaouali MA, et al. The relevance of the UPS in fatty liver graft preservation: a new approach for IGL-1 and HTK solutions[J]. Int J Mol Sci, 2017, 18(11): 2287.
46	Bailey-Elkin BA, Knaap RCM, Kikkert M, et al. Structure and function of viral deubiquitinating enzymes[J]. J Mol Biol, 2017, 429(22): 3441-3470.
47	Tobias JW, Varshavsky A. Cloning and functional analysis of the ubiquitin-specific protease gene UBP1 of Saccharomyces cerevisiae[J]. J Biol Chem, 1991, 266(18): 12021-12028.
48	Wolberger C. Mechanisms for regulating deubiquitinating enzymes[J]. Protein Sci, 2014, 23(4): 344-353.
49	Zhao YC, Wang F, Gao LC, et al. Ubiquitin-specific protease 4 is an endogenous negative regulator of metabolic dysfunctions in nonalcoholic fatty liver disease in mice[J]. Hepatology, 2018, 68(3): 897-917.
50	Zhou JQ, Qiu T, Wang TY, et al. USP4 deficiency exacerbates hepatic ischaemia/reperfusion injury via TAK1 signalling[J]. Clin Sci (Lond), 2019, 133(2): 335-349.
51	Zhou JQ, Wang TY, Chen ZB, et al. Ubiquitin-specific peptidase 10 protects against hepatic ischaemic/reperfusion injury via TAK1 signalling[J]. Front Immunol, 2020, 11: 506275.
52	Luo PC, Qin C, Zhu LH, et al. Ubiquitin-specific peptidase 10 (USP10) inhibits hepatic steatosis, insulin resistance, and inflammation through sirt6[J]. Hepatology, 2018, 68(5): 1786-1803.
53	Lai KP, Cheung AHY, Tse WKF. Deubiquitinase Usp18 prevents cellular apoptosis from oxidative stress in liver cells[J]. Cell Biol Int, 2017, 41(8): 914-921.
54	Schneider M, Zimmermann AG, Roberts RA, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB[J]. Nat Immunol, 2012, 13(9): 823-831.
55	Li ZT, Liu H, Zhang WQ. NLRC3 alleviates hypoxia/reoxygenation induced inflammation in RAW264.7 cells by inhibiting K63-linked ubiquitination of TRAF6[J]. Hepatobiliary Pancreat Dis Int, 2020, 19(5): 455-460.
56	Zhao Y, Majid MC, Soll JM, et al. Noncanonical regulation of alkylation damage resistance by the OTUD4 deubiquitinase[J]. EMBO J, 2015, 34(12): 1687-1703.
57	Liu H, Fan J, Zhang WQ, et al. OTUD4 alleviates hepatic ischemia-reperfusion injury by suppressing the K63-linked ubiquitination of TRAF6[J]. Biochem Biophys Res Commun, 2020, 523(4): 924-930.
58	Wang Q, Wei S, Li L, et al. TGR5 deficiency aggravates hepatic ischemic/reperfusion injury via inhibiting SIRT3/FOXO3/HIF-1a pathway[J]. Cell Death Discov, 2020, 6(1): 116.

[1]	Linfeng He, Yu Cao, Ning Zhang, Xinze Ran, Fengchao Wang. Regulation of intestinal stem cells and tissue damage and repair after radiation exposure [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(04): 358-363.
[2]	Kunhe Li, Mengjia Kou, Liting Kuang. Risk factors and prediction model of reintubation after liver transplantation [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 366-371.
[3]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Shanghai Pharmaceutical Profession Association. Expert Consensus on the Use of Mycophenolic Acid in Chinese Liver and Kidney Transplant Recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 257-272.
[4]	Wenqing Lu, Xinyi Chen, Xuefei Ren. Investigation on the quality of life after liver transplantation in children with genetic metabolic diseases [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 287-292.
[5]	Tieyan Fan, Jun Li, Hong Chen. Diagnosis and treatment experience of new onset viral hepatitis E after liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 293-296.
[6]	Shuo Chen, Feng Chen, Fei Cheng, Jie Xiang. Pancreas infarction after liver transplantation for glycogen storage disease type Ⅰ complicated with pancreatitis: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 300-302.
[7]	Penghao Tang, Wu Zhang. Progress in mechanism research about intestinal microecology with perioperative complications of liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 303-307.
[8]	Committee of Health Management for Organ Transplant Recipient, China Organ Transplantation Development Foundation, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Branch of Organ Transplant of Chinese Medical Association, National Center for Healthcare Quality Management in Liver Transplant. Chinese expert consensus on clinical application of inhibitors of mammalian target of rapamycin in liver transplant recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 193-204.
[9]	Qing Yan, Ying Liu, Feiwen Deng, Huanwei Chen. Effect of microvascular invasion on survival and prognosis of liver transplantation recipients with liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 624-629.
[10]	Mei Liao, Hongjun Zhang, Jieyang Jin, Yan Lyu, Jie Ren. Diagnostic value of bedside contrast-enhanced ultrasound for early hepatic artery thrombosis after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 630-634.
[11]	Binglin Li, Shaocheng Lyu, Fei Pan, Tao Jiang, Hua Fan, Jiantao Kou, Qiang He, Ren Lang. Correlation analysis between pathogenic bacteria of donor liver perfusion fluid and early infection after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 656-660.
[12]	Lei Lyu, Xiao Feng, Kaiming He, Kaining Zeng, Qing Yang, Haijin Lyu, Huimin Yi, Shuhong Yi, Yang Yang, Binsheng Fu. Value of revised King's score in evaluation of live transplantation timing for children with acute liver failure due to Wilson's disease and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 661-668.
[13]	Menglong Wang. Significance of biological characteristics in liver transplantation for HCC [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 490-494.
[14]	Minghan Guan, Zhiqiang Xue. Dextrmedetomidine in improving neurodegeneration after cerebral ischemia-reperfusion in rats [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2023, 09(05): 270-276.
[15]	Minjie Zhang, Xiaoshan Zhang, Shasha Duan, Yilu Shi, Jie Zhao, Tianhao Bai, Yaxi Wang. Hydrogen for treatment of myocardial ischemia-reperfusion injury: mechanism and prospect [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 744-748.

Please choose a citation manager

Content to export